Formulary
Tildrakizumab: Indications, Dosing, Side Effects and Interactions
Tildrakizumab is a recombinant human monoclonal antibody that specifically binds to interleukin-23 and inhibits the release of pro-inflammatory cytokines and...
MedNext Academy | 3 min read
Tildrakizumab: Indications, Dosing, Side Effects and Interactions
Tildrakizumab is a recombinant human monoclonal antibody that specifically binds to interleukin-23 and inhibits the release of pro-inflammatory cytokines and...
Drug action
Tildrakizumab is a recombinant human monoclonal antibody that specifically binds to interleukin-23 and inhibits the release of pro-inflammatory cytokines and chemokines.
Indications and dose
**Moderate-to-severe plaque psoriasis (under expert supervision)**
- **Adult** (By Subcutaneous Injection): Initially 100 mg, then 100 mg after 4 weeks, then maintenance 100 mg every 12 weeks, consider discontinuation if no response after 28 weeks, in patients with a high disease burden, or with a body weight 90kg, a dose of 200 mg may provide greater efficacy.
Cautions
Chronic infection; history of recurrent infection; recent serious infection Cautions, further information Risk of infection Manufacturer advises consider anti-tuberculosis therapy before initiation of tildrakizumab in patients with a history of tuberculosis, in whom an adequate course of treatment cannot be confirmed. Manufacturer advises consider completion of immunisations according to current guidelines before initiating treatment (consult product literature for appropriate interval between vaccination and administration of tildrakizumab).
Contraindications
Clinically significant active infection
Side effects
Common or very common Back pain; diarrhoea; headache; increased risk of infection; nausea
Interactions
**Other interactions (3):**
- Live vaccines should not be given concurrently with tildrakizumab (see section 4.4).
- Furthermore, tildrakizumab does not impact the pharmacokinetics of concomitant medicinal products metabolised by CYP450 enzymes either through direct or indirect mechanisms (see section 5.2).
- Interactions with other immunosuppressive agents or phototherapy The safety and efficacy of tildrakizumab in combination with other immunosupressive agents, including biologics, or phototherapy has...
Pregnancy
Manufacturer advises avoid-limited information available.
Breast feeding
Manufacturer advises avoid-limited information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Tildrakizumab in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

